Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The purpose of this study is to see if adding a drug called spironolactone with other drugs improves heart failure.
The aims of this study are to test the safety and effect of spironolactone compared with placebo. This treatment is for adults with heart failure with the abnormal pumping function of the main pump of the heart. Spironolactone is a """"""""potassium-sparing"""""""" water pill that removes extra water and prevents salt retention. Spironolactone is used to treat people with congestive heart failure. This drug is already approved by the Food and Drug Administration (FDA) for congestive heart failure. This study uses a lower starting dose of this drug that is not approved by the FDA and compares it to a placebo . This will test if the drug has a real effect.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54RR026137-03
Application #
8359896
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Project Start
2011-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
3
Fiscal Year
2011
Total Cost
$83,146
Indirect Cost

  Institution

Name
Morehouse School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
102005451
City
Atlanta
State
GA
Country
United States
Zip Code
30310

  Publications

Piano, Ilaria; Baba, Kenkichi; Claudia Gargini et al. (2018) Heteromeric MT1/MT2 melatonin receptors modulate the scotopic electroretinogram via PKC? in mice. Exp Eye Res 177:50-54
Owino, Sharon; Sánchez-Bretaño, Aida; Tchio, Cynthia et al. (2018) Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity. J Pineal Res 64:
Augello, Catherine J; Noll, Jessica M; Distel, Timothy J et al. (2018) Identification of novel blood biomarker panels to detect ischemic stroke in patients and their responsiveness to therapeutic intervention. Brain Res 1698:161-169
Ofili, Elizabeth O; Pemu, Priscilla E; Quarshie, Alexander et al. (2018) DEMOCRATIZING DISCOVERY HEALTH WITH N=Me. Trans Am Clin Climatol Assoc 129:215-234
Sánchez-Bretaño, Aída; Baba, Kenkichi; Janjua, Uzair et al. (2017) Melatonin partially protects 661W cells from H2O2-induced death by inhibiting Fas/FasL-caspase-3. Mol Vis 23:844-852
Laurent, Virgine; Sengupta, Anamika; Sánchez-Bretaño, Aída et al. (2017) Melatonin signaling affects the timing in the daily rhythm of phagocytic activity by the retinal pigment epithelium. Exp Eye Res 165:90-95
Chen, Xiaoming; Cobbs, Alyssa; George, Jasmine et al. (2017) Endocytosis of Albumin Induces Matrix Metalloproteinase-9 by Activating the ERK Signaling Pathway in Renal Tubule Epithelial Cells. Int J Mol Sci 18:
Simmons, Lauren J; Surles-Zeigler, Monique C; Li, Yonggang et al. (2016) Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway. J Neuroinflammation 13:237
Zhao, Xueying; Jiang, Chen; Olufade, Rebecca et al. (2016) Kidney Injury Molecule-1 Enhances Endocytosis of Albumin in Renal Proximal Tubular Cells. J Cell Physiol 231:896-907
Jockers, Ralf; Delagrange, Philippe; Dubocovich, Margarita L et al. (2016) Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol 173:2702-25

Showing the most recent 10 out of 71 publications